JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shen, S.
Right arrow Articles by Meredith, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shen, S.
Right arrow Articles by Meredith, R. F.

Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion Protein in Patients with Gastrointestinal Malignancies

Sui Shen, PhD1, Andres Forero, MD2, Albert F. LoBuglio, MD2, Hazel Breitz, MD3, M.B. Khazaeli, PhD1, Darrell R. Fisher, PhD4, Wenquan Wang, PHD5 and Ruby F. Meredith, MD, PhD1

1 Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama
2 Department of Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama
3 NeoRx Corp., Seattle, Washington
4 Pacific Northwest National Laboratory, Richland, Washington
5 Biostatistics Division, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama



View larger version (16K):

[in a new window]
  		FIGURE 1. Mean serum (•) pharmacokinetic values (%ID/mL) after injection of 90Y-DOTA-biotin. Error bars represent minimum and maximum values of 9 patients.

 


View larger version (39K):

[in a new window]
  		FIGURE 2. Serum concentration (%ID/mL) of 90Y-DOTA-biotin and 111In-DOTA-biotin measured in patients 4–9. Serum clearance between 90Y and 111In measurements was fairly close.

 


View larger version (18K):

[in a new window]
  		FIGURE 3. Transmission counts vs. source depth. 111In sources of 50 and 150 mL were used to simulate tumor and kidney/spleen, respectively. Source depth was defined as solid water thickness added to distance of source center from source surface. Caret (^) is exponentiation operator.

 


View larger version (18K):

[in a new window]
  		FIGURE 4. Transmission counts vs. source depth. 111In source of 1,570 mL was used to simulate liver ({triangleup}). Liver phantom transmission counts were also determined using 57Co sheet source (•). Source depth was defined as solid water thickness (2–24 cm) added to distance of source center from source surface. Caret (^) is exponentiation operator.

 


View larger version (36K):

[in a new window]
  		FIGURE 5. Whole-body images of 111In- DOTA-biotin immediately, 3 h, 1 d, 2 d, and 4 d after injection. Liver, spleen, kidneys, bladder, and tumors in liver were visualized above body background. Ant = anterior; Post = posterior.

 


View larger version (29K):

[in a new window]
  		FIGURE 6. Tumor %ID/g vs. time for 13 tumors in 7 patients.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.